A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Abstract Text:

M Patris,P Agussol,J M Alby,S Brion,G Burnat,D Castelnau,S Deluermoz,H Dufour,M Ferreri,M Goudemand,

A total of 186 patients who met the DSM-III criteria for schizophrenia were admitted to a double-blind randomized multicentre trial in which the efficacy and safety of remoxipride at two dose levels was compared with those of haloperidol. Over a period of six weeks the patients received remoxipride 100-300 mg/day (n = 60), remoxipride 200-600 mg/day (n = 61), or haloperidol 10-30 mg/day (n = 64). There was no significant difference between the three treated groups with regard to the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scores obtained. Remoxipride, at both dosage ranges used, thus had comparable therapeutic efficacy to that of haloperidol. In contrast, extrapyramidal symptoms occurred significantly more frequently in the group treated with haloperidol. Laboratory tests and cardiovascular investigations showed no specific drug effect in any of the treated patients. Remoxipride is thus effective in acute treatment of schizophrenia at both dosage levels and has an advantage over haloperidol in neurological acceptability.

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Publishing Authors By Initials

M Patris,P Agussol,JM Alby,S Brion,G Burnat,D Castelnau,S Deluermoz,H Dufour,M Ferreri,M Goudemand,

For similar behavioral disciplines and activities: schizophrenic psychology research abstracts see: behavioral disciplines and activities: schizophrenic psychology research

PUBMED ID PMID:

MEDLINE DATE:

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME: 358

Page Numbers: 78-82

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 1990

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Keywords Mesh Terms:

KEYWORDS: Schizophrenic Psychology

MESH TERMS: drug therapy

Chemical & Substance for Abstract: A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Information

Substance Name: Remoxipride

Registry Number: 80125-14-0

Grant and Affiliation Information for A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.

AFFILIATION: Clinique Psychiatrique, CHU de Strasbourg, France.

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol Related Publications

• A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.
• Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
• Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies.
• Not Available
• Pharmaco-economic aspects of inhibitor treatment.
• SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome.
• [Blood transfusion and the public health; the regional center of Lille.]
• [Not Available.]
• [Psychopathological basic of medical psychology]
• [Use of polyvinyl pyrrolidone in the agglutination test for incomplete Rh antibodies.]